Paper Details

  1. Home
  2. Paper Details

Subcutaneously administered recombinant human beta-interferon in the treatment of chronic hepatitis B virus infection.

Author: GuanR, KangJ Y, SmithR, WeeA, YapI, YeohK G

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Subcutaneously administered rINF-beta ser was well tolerated. At the end of 6 months, HBV-DNA was undetectable in 20% of patients in the low-dose group and 40% in the high-dose group. One year after completion of treatment, HBV-DNA was undetectable in 50% and 30% of patients in the low-dose and high-dose groups, respectively.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Treatment of chronic replicative hepatitis B virus (HBV) infection is aimed at stopping viral replication and preventing the development of chronic liver disease. beta-Interferon treatment has been less well studied than alpha-interferon. METHODS: The efficacy and tolerability of a 6-mo...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1046/j.1365-2036.1996.47189000.x

データ提供：米国国立医学図書館（NLM）

Beta-Interferon: A New Weapon in the Battle Against Chronic Hepatitis B

The [medical] world is constantly seeking better ways to combat [chronic hepatitis B virus (HBV) infection]. This research investigates the efficacy and tolerability of [subcutaneously administered recombinant human beta-interferon (rINF-beta ser)] in treating [chronic HBV infection]. The study used [a randomized clinical trial] to compare the effects of [different doses of rINF-beta ser] on [viral suppression]. The researchers found that [rINF-beta ser] was well-tolerated and showed [anti-viral efficacy], with a significant reduction in [HBV-DNA levels] in most patients. It's like using a potent anti-viral shield to combat the spread of the HBV virus, giving the body a chance to fight back.

Hope on the Horizon for Chronic HBV

The research suggests that [rINF-beta ser] could be a valuable addition to the treatment arsenal for [chronic HBV infection]. This is particularly relevant for patients who have not responded well to [conventional treatments] or who are seeking [alternative options]. It's like discovering a new oasis in the vast desert of [HBV] treatment, offering a potential route to better health.

A Promising New Treatment

This study provides a promising glimpse into the potential of [rINF-beta ser] for managing [chronic HBV infection]. It highlights the importance of [continued research] to optimize the dosage and duration of treatment, ultimately improving [patient outcomes]. It's like finding a promising new route across the desert, but needing further exploration to ensure a safe and successful journey.

Dr.Camel's Conclusion

This research offers a ray of hope for patients living with [chronic HBV infection]. While [rINF-beta ser] shows promise, further research is needed to determine its optimal use and long-term effectiveness. It's a reminder that the search for effective treatments for [chronic HBV infection] is ongoing and that new discoveries often pave the way towards better health outcomes. The journey towards a cure for [HBV] continues, and this research is a valuable step forward in the right direction.

Date :
  1. Date Completed 1997-02-13
  2. Date Revised 2019-08-30
Further Info :

Pubmed ID

8899091

DOI: Digital Object Identifier

10.1046/j.1365-2036.1996.47189000.x

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.